Retrospective study of nivolumab for patients with recurrent high grade gliomas

Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series

(2017) Marc C. Chamberlain et al.   JOURNAL OF NEURO-ONCOLOGY

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

(2017) Antonio Omuro et al.   NEURO-ONCOLOGY

OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143

(2017) D. A. Reardon et al.   NEURO-ONCOLOGY

Lomustine and Bevacizumab in Progressive Glioblastoma

(2017) Wolfgang Wick et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)

(2017) T. F. Cloughesy et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency

(2016) Eric Bouffet et al.   JOURNAL OF CLINICAL ONCOLOGY

ATIM-35. RESULTS OF THE PHASE IB KEYNOTE-028 MULTI-COHORT TRIAL OF PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT PD-L1-POSITIVE GLIOBLASTOMA MULTIFORME (GBM)

(2016) David A. Reardon et al.   NEURO-ONCOLOGY

Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial

(2016) Bogdana Suchorska et al.   NEURO-ONCOLOGY

PD-1 Blockers

(2015) Jedd D. Wolchok   CELL

Irinotecan-based regimens for recurrent glioblastoma multiform: a systematic review

(2015) Omar Abdel-Rahman et al.   Expert Review of Neurotherapeutics

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

(2015) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

(2015) Naiyer A Rizvi et al.   LANCET ONCOLOGY

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

(2015) E. Q. Lee et al.   NEURO-ONCOLOGY

Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma

(2015) Kathryn M. Field et al.   NEURO-ONCOLOGY

Introduction

(2015) David A. Reardon et al.   NEURO-ONCOLOGY

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Irinotecan-based regimens for recurrent glioblastoma multiform: a systematic review

(2015) Omar Abdel-Rahman et al.   Expert Review of Neurotherapeutics

Addition of lomustine for bevacizumab-refractory recurrent glioblastoma

(2014) Michaela Tonder et al.   ACTA ONCOLOGICA

Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies

(2014) Kathryn M. Field et al.   CANCER

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC)

(2014) Marc C. Chamberlain et al.   JOURNAL OF NEURO-ONCOLOGY

Are we done with dose-intense temozolomide in recurrent glioblastoma?

(2014) M. J. van den Bent et al.   NEURO-ONCOLOGY

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma

(2014) S. J. Han et al.   NEURO-ONCOLOGY

Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

(2013) E. Galanis et al.   CLINICAL CANCER RESEARCH

Standards of care for treatment of recurrent glioblastoma—are we there yet?

(2012) Michael Weller et al.   NEURO-ONCOLOGY

Salvage therapy with single agent bendamustine for recurrent glioblastoma

(2011) Marc C. Chamberlain et al.   JOURNAL OF NEURO-ONCOLOGY

Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?

(2011) J. L. Clarke  et al.   NEURO-ONCOLOGY

Hypofractionated Stereotactic Radiation Therapy: An Effective Therapy for Recurrent High-Grade Gliomas

(2010) Shannon E. Fogh et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of salvage reirradiation for malignant gliomas that progress on bevacizumab

(2009) Roy G. Torcuator et al.   JOURNAL OF NEURO-ONCOLOGY

Salvage therapy with single agent bevacizumab for recurrent glioblastoma

(2009) Marc C. Chamberlain et al.   JOURNAL OF NEURO-ONCOLOGY

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

(2009) Eudocia C. Quant et al.   NEURO-ONCOLOGY

Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience

(2009) P. L. Nghiemphu et al.   NEUROLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY